Selling diagnostic equipment in India:
the reagent decides the deal, not the device
Hospitals buy devices. India’s diagnostic and pathology chains buy cost per test. Get the placement model, the reagent lock in and the buying committee wrong, and the capital price you quoted becomes irrelevant before the deal is signed.
How is selling diagnostic equipment into India different from other medical devices?
The commercial model is usually not a device sale at all. Most capital equipment placed into Indian diagnostic and pathology chains runs on a reagent rental or managed-service contract: the manufacturer supplies the analyzer at little or no upfront cost and recovers the investment over a multi-year term through a locked consumable and reagent supply, often with a minimum daily test volume written into the agreement. The device price barely enters the conversation. What decides the deal is cost per reportable test, reagent supply reliability, turnaround time and uptime, because a down analyzer in a high-volume lab means samples get rerouted to a competing lab that same day.
The regulatory position is different too. India brings IVD kits and reagents under full CDSCO licensing, but the analyzer instrument itself has, at different times, sat outside that licensing scope under CDSCO's own published guidance. Montazzo runs the commercial side of this: channel, demand and the sales motion into pathology and diagnostic chains. We hold no import licence or IVD registration and are not anyone's India Authorized Agent.
By Tanveer Sinngh, Founder at Montazzo · Why doesn't the device price decide this sale?
Because in most of India's organized diagnostic sector, the device is not being sold. It is being placed.
| Commercial model | How it is priced | What actually decides the deal | Where you see it |
|---|---|---|---|
| Capital purchase The lab buys the analyzer outright. | A quoted device price, sometimes with a service contract bought separately. | Device price, service network, and whether the import paperwork is already done. | Smaller standalone pathology labs and hospital in-house labs buying one machine. |
| Reagent rental / placement The manufacturer supplies the analyzer for little or no upfront cost. | A multi-year term, with the investment recovered through locked reagent and consumable sales. | Cost per reportable test, reagent quality and supply reliability, and the minimum daily volume written into the contract. | Large diagnostic and pathology chains, and hospital labs running high test volumes. |
| Pay-per-result / managed service The vendor owns and services the equipment entirely. | A per-result fee, often bundled with maintenance, calibration and consumable logistics. | Turnaround time, uptime, and the reliability of the consumable supply chain into smaller towns. | Decentralised collection networks and labs in tier two and tier three cities that cannot carry capital cost. |
Placement and pay-per-result models have been used by some of India's largest hospital groups for well over a decade, and in capital-intensive categories they account for a meaningful share of how equipment actually enters a lab, not the exception to a capital sale. If your sales process is built around quoting a device price and negotiating a discount off it, you are selling into the minority of this market.
Does the CDSCO import licence cover the analyzer, or just the reagent?
This is the single most commercially consequential regulatory question in diagnostics, and the honest answer is that it depends on exactly what you are importing and when you check. India's Medical Device Rules, 2017 brought in vitro diagnostic kits and reagents under full CDSCO licensing from 2018, classified by risk from Class A, the lowest, to Class D, the highest, with mandatory pre-market performance evaluation for a defined set of IVDs, such as HIV test kits, before an import licence can issue.
CDSCO's own published guidance has, at different points, stated that the instrument, analyzer or software used alongside a licensed kit sits outside the IVD licensing requirement, only the kit or reagent itself needs one, while separately publishing classification lists that bring certain analyzers into scope directly. CDSCO revised its IVD risk classification system again in early 2026. That gap matters commercially: if your reagent is licensed and your analyzer is not, your Authorized Agent's paperwork covers only part of what is going into the lab, and the rest of the relationship, the placement contract, the service terms, the consumable supply, is a commercial matter rather than a regulatory one. Check the current scope for your specific IVD category directly with CDSCO before assuming either way.
A reagent rental contract does not wait for a full device registration process the way a capital import does, because the commercial terms sit outside the regulatory filing. That is also why we can run chain and lab targeting in parallel with your regulatory process rather than after it, the same way we do for capital medical devices.
Who actually decides, and what are they optimising for?
The buying committee is smaller and faster than a hospital capital purchase, and it is optimising for different things entirely.
- The lab director or pathologist in charge. Owns clinical validation of the reagent and platform, and cares most about correlation with the existing method and turnaround time on urgent results.
- Central procurement or supply chain, for the larger chains. Owns the placement contract itself: the minimum volume commitment, the reagent pricing schedule, and the exit terms if volumes fall short. In a multi-city chain this sits above any single lab.
- Operations and quality. Owns uptime, the calibration schedule, and whether the vendor's service response actually matches the SLA on paper. A machine down for two days in a high-volume lab is lost revenue, not an inconvenience.
- Finance. Prefers the placement model specifically because it moves the cost from capital to a predictable operating line, which is part of why reagent rental has spread as fast as it has in this sector.
Compare that with a hospital buying a capital device, where a clinical champion, biomedical engineering, procurement, finance and a medical superintendent all sign off separately over four to nine months. A diagnostic chain placement decision, once the reagent is clinically validated, routinely moves faster, because the economics are the whole argument and fewer people are needed to agree on them.
Does NABL accreditation change what you can sell?
Indirectly, and increasingly. National Accreditation Board for Testing and Calibration Laboratories accreditation for diagnostic labs is still voluntary in India, and by most industry estimates fewer than one in fifty of the country's diagnostic labs actually hold it. That is changing from the demand side rather than from a new law: health insurers are making NABL accreditation a condition of empanelment, and government schemes including CGHS have moved toward requiring it for their own in-house laboratories and reward accredited facilities with higher reimbursement rates.
What that means for an equipment and reagent vendor is that accreditation forces a lab to run documented calibration, traceability and quality systems, which makes labs more conservative about changing platforms once accredited and more demanding about the documentation you can provide alongside the reagent. Selling into a lab that is pursuing accreditation, or already holds it, is a different and generally better conversation than selling into one that is not, because the lab already has a reason to insist on the paper trail you should be providing anyway.
The shape of the Indian diagnostics market
Two things follow from a market this fragmented. First, the unorganized and hospital based majority is not a lesser opportunity, it is where most of the volume actually sits, and it buys on price and service rather than brand. Second, the organized chains expanding into smaller towns are the fastest growing part of the market and the part most likely to want a placement model rather than a capital purchase, because they are optimising capital for expansion, not equipment.
What Montazzo runs
We are a B2B demand generation and sales team, not a reagent or analyzer manufacturer and not a regulatory agent. On a diagnostic equipment engagement that means four things.
- Chain and lab mappingWhich diagnostic and pathology chains, hospital in-house labs and collection networks are expanding, where, and which platforms they currently run, so you know who is actually due a placement decision rather than guessing.
- Demand generation into the decision makersOutbound into lab directors, central procurement and operations leads at the chains, run from Indian sending infrastructure, in Indian business hours.
- The economics conversation, prepared in advanceWe bring back cost per test, minimum volume terms and service expectations in the buyer's own words, so your commercial team walks in with the real negotiation rather than a device pitch.
- The sales motion and loss reasonsQualification, follow-up that continues past the second email, and a written record of every objection, so year two is not a repeat of year one.
We do not manufacture or hold title to any equipment or reagent, we are not an India Authorized Agent, we hold no IVD registration or import licence, and we do not file with CDSCO. This page is not regulatory or legal advice. For the capital device side of this, including who holds what in the import process, read medical devices in India. For the demand side across the rest of Indian healthcare, see our hospital and clinic network, and if your distributor is also your Authorized Agent, read what that combination actually ties you to before you sign anything.
For the wider picture of entry routes, start at selling your product in India.
FAQ
Questions diagnostic and pathology equipment manufacturers ask us
Not automatically. The same Authorized Agent structure applies if your product needs an import licence at all, and the usual risks around combining the agent and distributor roles apply equally here. What is different is that a reagent rental or placement contract is a commercial agreement rather than a regulatory filing, so you can often start lab-level commercial conversations before the full import process is finished, provided you are not yet taking orders or implying the product is cleared for sale.
It is a normal, long-established commercial model in Indian diagnostics, not a workaround. Several of India’s largest hospital groups have run reagent rental contracts for over a decade, typically with a multi-year term and a minimum daily test volume built into the agreement. It sits alongside outright capital purchase as one of several standard ways equipment enters a lab, and in several capital-intensive categories it is the more common of the two.
No. Most Indian diagnostic labs are not NABL accredited and still buy and run equipment normally. What accreditation changes is how conservative a lab becomes about its documentation and its willingness to switch platforms once accredited, and it is becoming a practical requirement for labs that want insurer empanelment or certain government scheme reimbursement. A lab pursuing accreditation is often a more demanding and more durable customer, not a blocked one.
Mostly cash flow and growth plans. Chains expanding into new cities prefer to keep capital for new locations rather than equipment, so placement suits them. Smaller standalone labs or hospitals adding a single machine, with no immediate expansion plan, more often buy outright because the total cost over the equipment’s life is usually lower without a locked, multi-year reagent commitment. Ask which situation your prospect is actually in before you lead with a device price.
In most cases, yes, for the commercial side. Channel mapping, chain and lab targeting and early relationship building can run in parallel with the regulatory process, because the placement contract itself is a commercial matter, not a filing. What we will not do is take orders or make any claim that implies the device is cleared for sale before it actually is.
No. We generate the demand and run the sales motion up to the point of commercial negotiation; the pricing, contract terms and clinical validation sit with you and the lab directly, with your own commercial and technical teams in the room. We bring back what the lab says about cost per test, minimum volume and service expectations in their own words, so you negotiate with real information rather than a guess.
Tell us which Indian labs you are trying to reach
A 30-minute call. We tell you whether your category sells as a capital purchase or a placement contract in India, who actually decides, and what we would run.
Let's chat